Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

References for PMC Articles for PubMed (Select 17049078)

1.

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.

Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R.

Blood. 2007 Feb 1;109(3):1228-32. Epub 2006 Jul 13.

2.

The molecular classification of multiple myeloma.

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr.

Blood. 2006 Sep 15;108(6):2020-8. Epub 2006 May 25.

3.

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.

Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S.

Cancer Res. 2005 Dec 15;65(24):11345-53.

4.

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr.

Blood. 2005 Jul 1;106(1):296-303. Epub 2005 Mar 8.

5.

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM.

Cancer Cell. 2004 Feb;5(2):191-9.

PMID:
14998494
6.

Genetics and cytogenetics of multiple myeloma: a workshop report.

Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H.

Cancer Res. 2004 Feb 15;64(4):1546-58.

7.

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr.

N Engl J Med. 2003 Dec 25;349(26):2483-94.

8.

Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS.

Chim CS, Fung TK, Liang R.

Leukemia. 2003 Dec;17(12):2533-5. No abstract available.

PMID:
12970764
9.

Driving the cell cycle to cancer.

Malumbres M, Hunt SL, Sotillo R, Martín J, Odajima J, Martín A, Dubus P, Ortega S, Barbacid M.

Adv Exp Med Biol. 2003;532:1-11. Review.

PMID:
12908544
10.

Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.

Bergsagel PL, Kuehl WM.

Immunol Rev. 2003 Aug;194:96-104. Review.

PMID:
12846810
11.

Fas-associated factor 1, FAF1, is a member of Fas death-inducing signaling complex.

Ryu SW, Lee SJ, Park MY, Jun JI, Jung YK, Kim E.

J Biol Chem. 2003 Jun 27;278(26):24003-10. Epub 2003 Apr 17.

12.

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM.

Cancer Cell. 2003 Feb;3(2):185-97.

PMID:
12620412
13.
14.

The RB and p53 pathways in cancer.

Sherr CJ, McCormick F.

Cancer Cell. 2002 Aug;2(2):103-12. Review.

PMID:
12204530
15.

Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.

Krämer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, Goldschmidt H, Hehlmann R.

Leukemia. 2002 Sep;16(9):1844-51.

16.

Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival.

Mateos MV, García-Sanz R, López-Pérez R, Moro MJ, Ocio E, Hernández J, Megido M, Caballero MD, Fernández-Calvo J, Bárez A, Almeida J, Orfão A, González M, San Miguel JF.

Br J Haematol. 2002 Sep;118(4):1034-40.

PMID:
12199782
17.

CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells.

Tourigny MR, Ursini-Siegel J, Lee H, Toellner KM, Cunningham AF, Franklin DS, Ely S, Chen M, Qin XF, Xiong Y, MacLennan IC, Chen-Kiang S.

Immunity. 2002 Aug;17(2):179-89.

PMID:
12196289
18.

Regulation of the human cyclin-dependent kinase inhibitor p18INK4c by the transcription factors E2F1 and Sp1.

Blais A, Monté D, Pouliot F, Labrie C.

J Biol Chem. 2002 Aug 30;277(35):31679-93. Epub 2002 Jun 20.

19.

Multiple myeloma: evolving genetic events and host interactions.

Kuehl WM, Bergsagel PL.

Nat Rev Cancer. 2002 Mar;2(3):175-87. Review.

PMID:
11990854
20.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr.

Blood. 2002 Mar 1;99(5):1745-57.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk